Citigroup reaffirmed their neutral rating on shares of Relx (LON:REL) in a research report released on Wednesday morning, Digital Look reports. Citigroup currently has a GBX 1,880 ($24.57) price objective on the stock.
Several other equities research analysts have also weighed in on REL. JPMorgan Chase & Co. raised their price objective on Relx from GBX 1,900 ($24.83) to GBX 1,950 ($25.48) and gave the stock an overweight rating in a research note on Friday, July 26th. Liberum Capital reaffirmed a buy rating on shares of Relx in a research report on Friday, July 26th. Goldman Sachs Group raised their target price on Relx from GBX 2,123 ($27.74) to GBX 2,178 ($28.46) and gave the stock a buy rating in a research report on Tuesday, June 11th. Barclays decreased their target price on Relx from GBX 2,160 ($28.22) to GBX 2,100 ($27.44) and set an overweight rating for the company in a research report on Friday, July 26th. Finally, UBS Group reaffirmed a sell rating on shares of Relx in a research report on Friday, July 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of GBX 1,861.77 ($24.33).
Shares of REL traded up GBX 1 ($0.01) during trading hours on Wednesday, hitting GBX 1,913.50 ($25.00). 2,015,349 shares of the company were exchanged, compared to its average volume of 4,990,000. The company has a market capitalization of $37.24 billion and a P/E ratio of 24.82. The company has a quick ratio of 0.40, a current ratio of 0.45 and a debt-to-equity ratio of 308.02. The business’s fifty day moving average is GBX 1,937.96. Relx has a one year low of GBX 1,466.50 ($19.16) and a one year high of GBX 1,995.13 ($26.07).
Relx Company Profile
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Featured Article: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.